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Abstract 
Background: The intermediate filament vimentin is not normally exposed to the 
immune system, however when exposed, anti-vimentin antibodies (AVA) can be 
provoked. AVA have been implicated in the development of cardiac allograft 
vasculopathy (CAV), limiting the long-term benefits of cardiac transplantation.   
Our aim was to develop a more specific and sensitive assay for AVA than 
currently available and determine if low levels of AVA are associated with CAV. 
 
Methods: A multiplexed assay for AVA was designed and validated by parallel 
testing with a commercially available ELISA for AVA. Sera titration and 
competitive inhibition with soluble vimentin were used to assess sensitivity and 
specificity. Pre- and post-transplant sera from forty-six patients were tested 
under IRB approval. Post-transplant sera were obtained within 12 months after 
transplantation.  
 
Results: In parallel titration studies, the bead-based assay was found to be twice 
as sensitive as the commercially available ELISA. Competitive inhibition studies 
of five sera resulted in a mean of 60%±28% reduction of antibody binding, 
confirming the Luminex assay specificity.  The incidence of AVA in pre- 
ii 
transplant sera was 39.1%.   
Conclusions: A Luminex bead based assay for AVA was developed that is both 
specific and twice as sensitive as a commercially available ELISA.  Although a 
high incidence of AVA among cardiac transplant candidates was observed pre-
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 The intermediate filament vimentin is a large component of mesenchymal 
cells that compose the aortic and pulmonary arteries of the heart. Vimentin is not 
endogenously exposed to the immune system, however when exposed, the 
immune response can elicit Anti-Vimentin Antibody (AVA).  Antibodies have 
long been a contraindication to transplantation and up until recently only 
alloantibodies, predominantly HLA specific, were thought to be relevant.1  
Recent studies have focused on the development of non-HLA antibodies during 
the post-transplant period and their correlation to organ allograft rejection.2,3   
The development of highly specific antibody detection methods has progressed 
rapidly in the last ten years 1, however non-HLA targets have lagged behind.  
 Rapid and specific solid organ post-transplant antibody monitoring can be 
accomplished using Luminex® based technology or flow cytometry. The 
Luminex® 100/200 platform is a fluorometer; a system based on flow cytometry 
principles.4 This method was proposed due to the accurate, reproducible, and 
rapid use in detection of anti-HLA antibodies.  
 Post-transplant cardiac patients can generate autoantibodies to vimentin 
that cause accelerated rejection in the cardiac transplant population. 5 The 
progression of Transplant Associated Coronary Artery Disease (TxCAD) and  
1 
Cardiac Allograft Vasculopathy (CAV) has been associated with the presence of 
AVA, limiting the long-term benefits of cardiac transplantation.3 TxCAD and 
CAV are characterized by a complex interaction of immunologic and non-
immunologic factors, which result in coronary obstruction. CAV is currently the 
most frequent cause of morbidity and mortality post orthotopic cardiac 
transplantation.6 The development of AVA could indicate a higher risk for CAV 
development and graft dysfunction. By monitoring the presence of AVA in post-
transplant recipients, the mortality of CAV could decrease.  
 In this analysis, I describe the development of a highly sensitive assay to 













 The cellular cytoskeleton is composed of five different classes of 
intermediate filament (IF) proteins. Vimentin (57 kDa), is a class III IF, and is 
found in cells of mesenchymal origin (endothelial cells, smooth muscle cells and 
leukocytes) and aids in structural integrity. Two vimentin monomers compose 
the smallest functional vimentin unit as a coiled-coil dimer. This unit is the 
building block for vimentin polymer assembly. 1,2 In addition to structural 
integrity, vimentin is important in cytosolic organelle position and is not 
intrinsically expressed on the extracellular surface. Vimentin is also expressed 
near proliferating or migrating smooth muscle cells, in the tunica intima of blood 
vessels. This layer of cells is composed of endothelial cells (vascular endothelial 
cells) and is in direct contact with the blood supply.3   
 
Organ damage and vimentin exposure 
 Organ tissue experiences trauma throughout the transplant process, 
which leads to apoptosis and necrosis post transplantation. 3 The mechanism of 
vimentin exposure to elicit an antibody response is not fully understood; 
however, recent studies indicate activated platelets, monocytes and lymphocytes  
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can secrete or express vimentin on the extracellular surface.4-7  The presence of 
vimentin within the extracellular space provides an initiation step in the 
development of AVA. The action of AVA binding to surface vimentin on 
circulating leukocytes induces the release of tissue factor, formally known as 
thrombokinase, expression of P-selectin, vimentin and additionally, tissue factor 
by platelets, resulting in the formation of platelet:leukocyte (P:L) conjugates. P:L 
conjugates have an increased ability to adhere to activated endothelial cells and 
elicit T cell activation through release of tissue factor, enhancing the exposure of 
vimentin to the immune system.7  Damaged cells that undergo apoptosis have 
also been observed to express vimentin on the extracellular surface. 8-11 Current 
evidence would support two mechanisms of vimentin exposure leading to 
transplant associated coronary artery disease:  
A) Apoptotic endothelial cells (donor origin) 
B) Circulating activated lymphocyte cascade (recipient origin) 
  
Coronary Allograft Vasculopathy and Endothelialitis 
 Coronary allograft vasculopathy (CAV) is the leading cause of morbidity 
and mortality post orthotopic heart transplantation, found in 42% of patients five 
years post-transplant.12 The invasive coronary angiography is considered the  
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standard for CAV diagnosis, however intravascular ultrasound can also be used 
to determine the thickness of a transplanted artery.13 Unfortunately, re-
transplantation is the only definitive cure for CAV. The true underlying cause of 
CAV is still unknown; however it is thought to be an immunologic phenomenon, 
resulting from an inflammatory response, leading to smooth muscle cell 
proliferation and coronary obstruction.  A recent study examined cellular 
infiltrates from the vessel walls of a patient with CAV and indicated a 
distinguished presence of T-cells localized in the neointima and the adventitia.14 
This particular cell population is associated with endothelialitis, and localization 
associated with chronic rejection. Endothelialitis is a constant state of endothelial 
cell inflammation in the allograft vascular wall which can lead to accelerated 
atherosclerosis.15 The culmination of these immunologic events can result in 
vascular permeability (of immunological infiltrates) and endothelial injury 
(perhaps exposing vimentin to extracellular spaces). It is believed the continued 
presence of tissue-specific immunity (anti-intermediate filament antibodies) 





Endothelialitis can activate smooth muscle cells to proliferate and migrate 
to the intima as an effect of injury.20 The smooth muscle cells produce cytokines 
during proliferation (e.g., TNF-α) which have been shown to trigger secretion of 
vimentin from monocytes.  Elevated TNF-α levels have been associated with 
CAV.5,21 Additionally, ischemic reperfusion injury can cause stress to the tissues, 
resulting in pro-inflammatory cytokines correlated with CAV development. The 
injury to the endothelial cell layer and activated smooth muscle cells may result 
in the exposure of vimentin to the extracellular surface and generation of anti-
vimentin antibody21. 
 
Rejection in the cardiac allograft 
 Donor specific antibodies (DSA) have been accepted as a contraindication 
to solid organ graft survival 22,23.  Antibody mediated rejection (AMR) occurs via 
the humoral immune response upon DSA binding to the donor heart 
endothelium.  The most egregious antibodies are directed to mismatched HLA 
antigens and can pre-exist or develop de novo post-transplant. The immune 
response causing AMR is activated predominantly through the classical pathway  
of the complement cascade.24 Through this mechanism, downstream complement 
complexes form a membrane attack complex (MAC) and initiate cell lysis.  
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Complement activation can occur without cells lysis, concluding in endothelial 
cell activation and chronic inflammation.25 Complement independent 
mechanisms can also activate endothelial cells via direct cross-linking of HLA on 
the endothelial cell surface. As discussed in the progression of CAV, activated 
endothelial cells will produce growth factors (fibroblast growth factor, platelet 
derived growth factor, cytokines and adhesions molecules) aiding the 
inflammation. The inflammation can be further aided via interaction of immune 
effector cells (macrophages, neutrophils and natural killer cells) and Fc 
receptors.26 The cumulative effect of complement dependent and independent 
immune functions can result in injured or activated endothelial cells and CAV 
development.27-29  
 The role of non-HLA antibodies, such as AVA, in the development of 
AMR is an active area of research, and non-HLA antibodies are also likely 
capable of injuring the allograft via complement dependent and independent 
mechanisms. AMR can result in graft dysfunction, worsen graft survival and 
result in a higher incidence of CAV.27,30 Until a recent meeting held in 2010 by the 
International Society for Heart and Lung Transplantation (ISHLT), the diagnosis  
of AMR was unstructured across transplant centers. This presented difficulty 
when assessing the impact of AMR on the patient population. Since 2010, AMR  
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has been defined by “histopathological and immunophenotypic criteria and does 
not require clinical dysfunction or serological evidence of donor-specific 
antibody production.”31 Defining AMR is important because historically a major 
criterion of AMR was the presence of HLA-specific DSA even though AMR may 
occur in the absence of HLA-specific DSA.32  
Anti-vimentin antibody detection methods  
 Solid phase immunoassays including indirect immunofluorescence, 
ELISA and western blot have been used for detection of anti-vimentin antibody 
over the past 25 years17,19,30,33. Anti-vimentin antibody has long been a focus of 
auto-immune diseases19; however, it has recently been correlated with 
CAV.9,12,17,28,31,34,35 Antibody detection methods have changed since researchers 
began identifying alloantibodies. Previous to laser technology, complement 
dependent lymphocytotoxicity (CDC) testing of sera was used to evaluate the 
presence of donor reactive antibodies.  The CDC test lacked consistency and was 
subjective.  To enhance specificity for certain antigens, the enzyme linked 
immunosorbent assay (ELISA) was adopted and later used to access anti-
vimentin antibodies17,19. This assay used a plate coated with vimentin protein. 
The serum incubated on the plate and antibody binding was detected generally 
with a horseradish peroxidase-conjugated anti-human IgG antibody. Addition of  
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the enzyme substrate, O-Phenylenediamine dihydrochloride, resulted in an 
enzymatic reaction indicative of primary antibody binding. The reaction results 
in a color change which is measured at a specific optical density. 18 
Unfortunately, the ELISA method is unable to detect very low-level antibodies 
present in the serum. However, the Luminex® fluoroanalyzer can detect 
antibodies well below that of ELISA. While flow cytometry can also be used to 
detect anti-vimentin antibody 36, it is more time consuming. With an ability to 
detect lower level concentrations, the presence of antibody could be detected 
before it becomes clinically symptomatic. The Luminex® technology is currently 
being used in many transplant immunology laboratories, mainly due to its 
accuracy, reproducibility, and high throughput. 
Luminex Technology 
 Early detection of low-level antibodies in post-transplant recipients is vital 
 to graft function due to the effects that rejection can have on the organ tissue. 
The Luminex® Fluoroanalyzer screening technology has brought a highly 
sensitive and specific instrument to the frontline of solid-phase immunoassay 
development. Rapid and specific solid organ post-transplant antibody 
monitoring can be accomplished using Luminex® based technology.  
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The Luminex® 100/200 platform is a fluorometer; a system based on flow 
cytometry principles. The analyzer uses two lasers, the first to detect 
microspheres that are impregnated with a unique combination of two dyes and 
coupled with different proteins.   The second laser identifies the secondary 
detection antibody.   The sample flows through a sheath delivery system where 
the antibodies bound to the beads are detected by the lasers. This method was 
proposed due to the accurate, reproducible, and rapid use in detection of anti-
HLA antibodies.37  
 
Post-transplant cardiac patients can develop autoantibodies to vimentin. 
The presence of AVA has been reported to cause accelerated rejection in the 
cardiac transplant population. 17,30,34-36 The progression of CAV has been 
associated with the presence of AVA, limiting the long-term benefits of cardiac 
transplantation. By monitoring the presence of AVA in post-transplant 
recipients, clinical intervention could decrease the mortality of CAV. Post-
transplant monitoring for AVA could allow detection of low-level antibodies, 
before they can lead to graft dysfunction. Using the Luminex platform and 
seroMAP bead technology, we produced a sensitive detection method, which has 
higher detection of AVA over that possible with the current commercially  
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available ELISA kits. This assay can facilitate post-transplant monitoring of 
cardiac transplant recipients to evaluate the presence of AVA and provide 


















Materials and Methods 
Patient study group and samples 
 Sixty-three patients who received orthotopic cardiac allografts at Johns 
Hopkins Hospital were analyzed in this IRB approved study (NA_00077525). The 
serum samples were chosen on accessibility, receipt of heart transplant and 
availability of clinical data. All serum samples were stored according to 
laboratory protocol to preserve reactivity. All serum specimens were obtained 
for routine clinical testing.   
Acute rejection 
 Routine endomyocardial biopsies were performed post-transplant. 
Biopsies were evaluated for acute rejection and graded with the 2005 
International Society of Heart and Lung Transplantation (ISHLT) criteria.6 
Multiplex assay bead activation and protein coupling 
 Recombinant human vimentin (R&D Systems, Inc., Minneapolis, MN, 
USA) was attached to Luminex SeroMAP™ microspheres using the 
manufacturer provided procedure, “Sample protocol for two-step carbodiimide 
coupling of protein to carboxylate microspheres”.4 Addition of the vimentin 
protein was titrated using 1ug, 5ug, 25ug and 125ug amounts of protein and  
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evaluated using phycoerythrin (PE)-conjugated rat monoclonal anti-human 
vimentin antibody (R&D Systems, Inc., Minneapolis, MN, USA). This process 
was repeated using Human IgM Purified Immunoglobulin (Sigma-Aldrich, Inc., 
MO, USA) and detected with phycoerythrin (PE)-conjugated goat polyclonal  
anti-human IgM antibody (Life Technologies, Frederick, MD, USA).  A naked 
bead was activated using the same protocol, with no protein attachment to serve 
as an internal negative control for non-specific binding (Table 1). 
Table 1. Luminex multiplex test composition.  
Control sera 
Control sera were comprised of a commercially available NAB (pooled 
normal AB blood-type non-sensitized male sera) and a Pooled Positive Control 
(PPC). The PPC was made by pooling sera from patients confirmed positive on 
the ELISA assay. 
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Bead Purpose 
1-Human IgM Positive Control 
2-Recombinant Vimentin Detection of anti-vimentin antibody 
3-no antigen Assess the background of the assay 
Luminex multiplex assay procedure 
Sera were incubated with the micro-bead suspension and PBS-TBN 
(.1%BSA, .02% Tween-20, .05% Azide, pH7.4) at a 1:25 dilution on a 
Multiscreen® filter plate in the dark for 30 minutes at 22 degrees Celsius. 
Following incubation, five washes of 250uL using PBS-TBN were performed. A 
secondary antibody, Phycoerythrin (PE)-conjugated goat polyclonal anti-human 
IgM antibody, was added at a 1:25 dilution and incubated in the dark for an 
additional 30 minutes at 22 degrees Celsius. Binding of AVA antibodies were 
detected using the Luminex® 100/200™ fluorometer platform. Results were 
reported as median fluorescence intensities (MFI). 
Semi-quantitative ELISA assay procedure 
 The ELISA was performed according to the VIDIA’s instructions. 
Absorbance was measured at 450nm using an Opsys MR™ Microplate reader 
and reported as optical density. 
Test results interpretation 
 To control for inter-assay variation, test results were normalized to the 
negative control (NAB) as ratios of the test bead MFI to NAB test bead MFI. A 
Luminex ratio greater than 1.25 was interpreted as positive. The ELISA sample 
positivity was determined by the manufacturer to be a ratio greater than 1.34.  
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Competitive inhibition by blocking 
 Serum was titrated at 1:5, 1:10, 1:25 and 1:50 then incubated with 2ug 
soluble vimentin for 10 minutes at 4 oC and 20 minutes at 22 oC prior to being run 
on the Luminex assay.  
Statistical Analyses 
Differences in distribution were assessed by the chi squared and Fischer’s 
exact test. A p value ≤ 0.05 was considered statistically significant. Test 
variability was determined using the coefficient of variation. A coefficient of 










Titration of protein coupling 
 A titration suggested by Luminex® using varying amounts of Human 
Recombinant Vimentin and IgM was performed to determine the optimal 
amount of protein for each bead. The vimentin test bead was optimized at 125ug 
and detected with phycoerythrin (PE)-conjugated rat monoclonal anti-human 
vimentin antibody (R&D Systems) and the IgM positive control was optimized at 
5ug and binding verified with phycoerythrin (PE)-conjugated goat polyclonal 












Figure 1. Protein coupling titration. The blue line measures the vimentin test 
bead MFI and the red dashed line measures the internal IgM positive control 
MFI. The vimentin titration could not be completed but due to the comparable 
size of the vimentin protein and HLA, however, the saturation levels observed 
using 125ug of vimentin are approaching saturation levels we observe on HLA 
Luminex assays and therefore the use of 125ug was considered comparable. 
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Titration of secondary detection antibody  
 The secondary antibody, Phycoerythrin (PE)-conjugated goat polyclonal 
anti-human IgM antibody (Life Technologies) was titrated from 1:25 to 1:1000 to 
optimize results. The experiment was carried out following the first incubation, 
of beads and sera, for 30 minutes at 22 degrees Celsius. The signal was 
maximized at 1:25, a level comparable to commercial Luminex bead based tests.  
 
Figure 2. Secondary antibody titration was performed using NAB serum and PE-
conjugated anti-human IgM antibody. The reactivity fell off quickly and linearly. 
The detection antibody was used at 1:25, indicated with the red marker. 
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Analyses of test reproducibility 
 In an effort to evaluate test reproducibility the NAB and the Pooled 
Positive Control (PPC) sera were tested in quadruplicate on the Luminex assay. 
The coefficients of variation were 0.07 and 0.10, respectively. For an assay with 
the sensitivity of Luminex, a coefficient of variation less than or equal to 0.10 was 
considered acceptable.  It was important to establish the reproducibility of this 
test for interpretation and quality control purposes.  (Figure 
3)
 
Figure 3. Analysis of test reproducibility. The blue bars measure the vimentin 
test bead MFI. The internal IgM positive control bead was graphed across 
samples to ensure comparable detection levels (StDev= 554MFI).  
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Optimization of test sensitivity 
 To ensure we were observing the optimal signal-to-noise ratio the PPC 
was titrated from 1:5 through 1:2000, as indicated in Figure 4. The vimentin test 
bead signal to the naked bead signal determined the signal-to-noise ratio. The 
ELISA kit controls were tested as a reference. The signal-to-noise was optimized 
at 1:25, with a decrease in signal at 1:50. All sera were tested at 1:25.   
Figure 4. The PPC and the ELISA kit controls were tested. The light blue bars measure 
the vimentin test bead MFI. The blue bars indicate the naked bead MFI. All MFIs are 
measure on the left y-axis. The signal to noise ratio is indicated by the dashed line and 




  To compare sensitivity levels, results from a commercially available 
ELISA kit were correlated with those from the Luminex multiplex assay. Fifty-
seven sera from heart patients were tested in parallel. The Luminex sample 
positivity was normalized to the NAB as ratios of the serum test bead MFI to 
NAB test bead MFI. The distribution of negative and positive samples was not 
statistically different however as evident in the upper left quadrant, there were 
numerous samples positive by Luminex that were negative by ELISA.  
  
Figure 5. Multiplex assay comparison. The vertical dashed line indicates the 
positive ELISA threshold and the horizontal dashed line indicates the positive 
Luminex threshold. Chi-squared is equal to 2.379, p-value=0.12, R=.202. 
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Competitive inhibition using soluble vimentin 
 To confirm the Luminex positive only sera were detecting anti-vimentin 
antibody, a competitive inhibition test using 2μl soluble vimentin was 
performed. The test indicated an observed 95% inhibition at the lowest serum 
dilution, as indicated in figure 6. 
  
Figure 6. Competitive inhibition experiment. The y-axis measures the percent 
blocking observed with each dilution tested, indicated by the blue bars.  
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Competitive inhibition studies: continued 
 Competitive inhibition studies were performed at a 1:50 dilution to confirm the 
antibodies detected by the Luminex® AVA assay in sera that tested negative by the 
standard ELISA assay were specific to vimentin and the results obtained previously 
were not unique to the specific serum sample. The 1:50 dilution was used due to the 
observed inhibition in previous experiments.  Five sera were tested and demonstrated 
inhibition of the signal with a mean inhibition of 60% and a standard deviation of 23.85.   
Sample MFI blocked MFI unblocked % Inhibition 
1 189 1108 82.9 
2 362 555 34.8 
3 718 993 27.7 
4 301 1154 73.4 
5 149 806 81.5 
Mean ± SD 343.5 ± 202 923.1 ± 220 60 ± 23.8 
Table 2. Competitive inhibition study of ELISA negative, Luminex positive sera. 
Five sera were tested. The unblocked and blocked raw MFI are shown. The % 




Serial dilution sensitivity trial 
 The sensitivity of the Luminex® AVA assay was evaluated by titration of 
the endpoints of detection of AVA in parallel tests of serial dilutions of sera 
documented to be positive in the standard ELISA assay. Detection of AVA in the 
Luminex® assay in dilutions that tested negative in the ELISA assay helped 
establish the degree of increased sensitivity.  (Under normal test conditions the 
ELISA is tested at 1:100 and the Luminex® assay at 1:25). Sample 1 and 2 
reactivity remained detectable by ELISA through the 1:400 dilution, while both 
samples AVA reactivity remained detectable by the Luminex® assay through the 
1:800 dilution. With these data the Luminex assay is observed to have a two-fold 










Figure 7.  Parallel test results of two serum samples were run.  S1 and S2 refer to 
samples 1 and 2. ELISA results are designated with “-E” and Luminex results 
with “-L”. The ELISA and Luminex Ratio are plotted on the left y-axis. The 
luminex assay was shown to be twice a sensitive as that of the ELISA, as 





Cardiac transplant recipient characteristics 
 The study group consisted of 63 patients: 35 (55%) females and 28 (44%) 
males. Patient characteristics are listed in Table 3. The overall incidence of CAV 
was 8/63.  There was no correlation with race or gender. 
 
Gender                 Coronary Allograft Vasculopathy (CAV) 
 Male    28  CAV Positive  8 
  African American 9  AVA +   2 
  Caucasian  18  AVA-    6 
  Asian   1  
  Hispanic  0  CAV Negative  42  
       AVA+    13 
       AVA-    29 
 Female   35  
  African American 19  No CAV data Available 13  
  Caucasian  12  AVA+    9  
  Asian   3  AVA-    4 
  Hispanic  1  
 
Table 3. Patient characteristics are listed in the left column. CAV status and AVA 
result are shown in the right column. There was no AVA correlation with 





 Due to possible vimentin exposure from tissue damage and AMR, HLA 
antibody was evaluated. 30/63 patients were sensitized to HLA class I antigens 
and 25/63 patients were sensitized to HLA class II antigens. 26/63 were un-
sensitized to HLA. Additionally the presence of HLA donor specific antibody 
was trending towards significance when correlated with AVA positivity. 
    
                 HLA- Specific Antibody   
    Class  I (p=. 34)  Class II (p= .28)   
     CI -  CI+   CI-     CI+   
 AVA-   20 15    23     12     
 AVA+   13 15    15     13    
  
 
     Donor Specific Antibody (p=0.05) 
      DSA-  DSA+ 
    AVA-  28  7 
    AVA+  16  12 
 
Table 4. HLA sensitization (n=63) was evaluated. The presence of HLA specific 
antibody did not correlate with the presence of AVA, however, DSA positivity  




 The presence of AVA was further evaluated by time point post-transplant. 
Forty-six of the 63 patients had a pre-transplant sample and at least one sample 
post-transplant within 1 year. A pre- and post-transplant sample was needed to 
evaluate each patient at more than one time-point. Of the 18 patients positive 
pre-transplant, 12 converted to negative post-transplant within 30 days of 
transplant, and 2 took more than 90 days to convert to AVA negative. Four of the 
18 patients remained positive post-transplant.  
 









AVA- - 12 - - 2 
AVA+ 18 1 1 - 2 
 
 
Table 5. Time point post-transplant where patients AVA+ pre-transplant 
converted to AVA-. Fourteen patients converted to AVA negative within 12 
months and 4 patients remained AVA+ post-transplant. 
 
28 
       AVA negative AVA positive 
CMR +(p=.97)     14   9  
AMR+ (p=.24)      6   2 
Table 6. Rejection and Pre-transplant AVA status. The distribution of AVA  
positivity and rejection status was not statistically significant in pre-transplant  
samples. 
Lastly, six patients converted from AVA negative to AVA positive. Fifty-percent  
(3/6) of these patients had a rejection episode (2CMR, 1 AMR and CMR) within  
six months of AVA positivity, although AVA positivity could not predict an  



















Conclusion and Discussion 
 
 This study supports the design of a successful Luminex multiplex assay, 
which has a higher detection of AVA than ELISA.  A main concern when 
designing a Luminex-based serum assay is the signal-to-noise ratio. To maximize 
the test signal, sera were tested at a 1:25 dilution. In early experiments (data not 
shown) the NAB exhibited an unexpected elevated signal. In an attempt to 
reduce the test background two filter plate companies were evaluated, NAB sera 
were ultra-centrifuged and different wash buffer compositions were evaluated. 
We found tween-20 to be a necessary component in the wash buffer as it acts as a 
detergent preventing the beads from sticking to the filter plate.  
 Ultracentrifugation did not provide an additional decrease in background. 
Additionally, hypotonic dialysis is a procedure used to remove interfering 
factors from patient serum. This alternative to reducing background through 
hypotonic dialysis could not be performed because it would have resulted in 
removal of the target IgM antibody.38 Due to the retrospective nature of the sera 
tested, the integrity of the IgM should be considered. 39 The stability of the IgM 
after repeat freeze thaw cycles coincides with a significant loss of reactivity on 
immunoassays. This indicates the need for a prospective study, which would 
provide better quality sera to determine if stronger signals could be achieved.  
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 The test procedure was derived from the Single Antigen Bead Assay (One 
Lambda, Inc.) 40. In the development of this assay the number of washes and 
incubation periods were not altered. Because the seroMAP technology on the 
Luminex platform has been established as achieving high sensitivity, we 
followed a standard protocol. In this regard we did not alter these variables.  
 The ELISA assay was considered to be the current standard and compared 
to the AVA Luminex assay. The two-fold increased sensitivity of the Luminex 
assay observed over the ELISA has previously been reported.41 The competitive 
inhibition experiment revealed the sera positive by Luminex only, are indeed 
identifying vimentin specific antibody. This is suggestive that the sera positive 
by Luminex only are true positives not identified by the ELISA. 
 The Luminex assay has shown to provide reproducible, sensitive and 
specific results. A weakness in evaluating the presence of AVA in the target 
population was a lack of statistical power due to a small sample size. To power a 
statistically relevant conclusion between AVA Luminex positive sera and 
orthotopic heart transplant recipients, more sera will need to be tested, obtaining 
sera at all time points for all patients post-transplant. Additionally, an 
appropriate negative control group would need to be determined. This would 
eliminate relying solely on the NAB to access a negative sample. 
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 The successful design of a Luminex multiplex assay for the detection of 
anti-vimentin antibody has clinical application.. A small study group (n=46) was 
evaluated and demonstrated an expected distribution of AVA, but the sample 
size did not provide the power needed to establish statistically relevant results. 
Although this assay was originally proposed for post-transplant monitoring of 
AVA, 18/46 patient’s pre-transplant samples were positive for AVA. The 
presence of AVA could not correlate with CAV in this study; however, the 
presence of low-level antibody pre-transplant may be a predictor of long-term 
poor outcomes. Due to this, additional studies should focus on outcomes greater 
than 12 months. Of the 18/46 initially positive patients, 12/18 converted to 
negative post-transplant and 4/18 remained AVA positive. This turn to AVA 
negative may be a dilution effect from the number of transfusions these patients 
endure during the transplant process, equivalent to a whole body transfusion. 
Even though AVA was not found to be a predictor of CAV in this patient group, 
we found no difference in the distribution if patients were sensitized to HLA or 
experienced rejection; however, the AVA positivity in the presence of DSA was 
trending toward significance and should be considered in future studies. 
Additionally, it has also been shown with other auto-antibodies and minor 
histocompatibility antigens the deleterious effects are observed in the long term. 
32 
 In conclusion, the Luminex multiplex assay was determined to be twice as 
sensitive as ELISA. Although high background can interfere with the AVA 
signal, reproducible, sensitive and specific results can be produced.  To power a 
statistically relevant conclusion between the presence of AVA and CAV, a larger 
prospective study needs to be conducted. Even though near 40% of pre-
transplant samples tested positive for AVA, long-term outcomes should be 
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